Registration Now Open!
NCCN 2022 Annual Congress: Hematologic Malignancies™
Friday, October 14, 2022 – Saturday, October 15, 2022
New York, New York
Virtual attendance option available
The NCCN 2022 Annual Congress: Hematologic MalignanciesTM is a 1.5-day, CE-certified event focused on the latest advances in hematologic malignancies. Chaired by Andrew D. Zelenetz, MD, PhD, from Memorial Sloan Kettering Cancer Center, this program features panel discussions with world-renowned experts, interactive presentations, and challenging patient cases that highlight recent updates to the NCCN Guidelines®, new and emerging therapeutic agents, and practical management strategies for patients with hematologic malignancies.
Register now for access to high-quality educational content, networking opportunities, and more. Attendees have the option to attend either in-person in New York or remotely through a virtual event platform.
In-person and virtual attendees will have full access to all on-demand sessions, the ability to attend all live sessions, an opportunity to engage in interactive question-and-answer sessions with speakers, and access to the NCCN Exhibition Hall.
Agenda topics include:
|
|
For CE program supporter opportunities, contact Lisa Perfidio, Senior Manager, CE Supporter Outreach.
Visit the NCCN Exhibition Hall in-person and virtually for networking opportunities and to gather the latest information from industry-sponsored exhibits, the Patient Advocacy Pavilion, and more.
For exhibitor opportunities, contact Jennifer Tredwell, Vice President, Marketing and Communications
NCCN 2022 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™
Saturday, October 15, 2022
New York, New York
Registration is separate from the NCCN Hematologic Malignancies Congress. Virtual attendance option available.
Topics Include:
Accreditation
This program is approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.
Recorded Presentations from the NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™ are now available.
Supported by educational grants from AstraZeneca; Daiichi Sankyo; Gilead Sciences, Inc. and Kite, A Gilead Company; GlaxoSmithKline; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer Inc.; Seagen Inc. (formerly Seattle Genetics, Inc.); and Takeda. This educational activity is supported by a medical education grant from Karyopharm® Therapeutics. This activity is supported by independent medical education grants from ADC Therapeutics, Pharmacyclics LLC and Janssen and Jazz Pharmaceuticals. This activity is supported by an independent educational grant from Merck & Co., Inc. This activity is supported by an independent medical education grant from Bristol Myers Squibb. Provided by an independent medical education grant from MorphoSys.
Save the dates!
NCCN 2023 Annual Congress: Hematologic Malignancies™